(S)-2-amino-5-methyl-4-oxo-hexanoic acid | 120794-42-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-5-methyl-4-oxo-hexanoic acid
• 英文别名: (S)-2-Amino-5-methyl-4-oxo-hexansaeure；(2S)-2-amino-5-methyl-4-oxohexanoic acid
• CAS: 120794-42-5
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: MHDVJWFLCVCFAR-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methylenecyclopropylalanine 在 盐酸 作用下， 生成 (S)-2-amino-5-methyl-4-oxo-hexanoic acid
  参考文献：
  名称：

  Ellington et al., Journal of the Chemical Society, 1959, p. 80,84

  摘要：

  DOI：

文献信息

• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• Compositions and methods for the treatment of chronic pain
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US11000487B2

  公开（公告）日：2021-05-11

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶解物、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII、式 VIII、式 IX、式 X、式 XI、式 XII、式 XIII、式 XIV 和式 XV 化合物的药物组合物以及治疗慢性疼痛的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。此类组合物可用于治疗慢性疼痛。
• Compositions and methods for the treatment of oral infectious diseases
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US11225463B2

  公开（公告）日：2022-01-18

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶剂、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII、式 VIII、式 IX、式 X、式 XI 和式 XII 化合物的药物组合物以及治疗口腔感染性疾病的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些成分可用于治疗口腔传染病。
• Immunoproteasome inhibitors
  申请人：Principia Biopharma Inc.

  公开号：US11225493B2

  公开（公告）日：2022-01-18

  Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本文提供的化合物，如式（I）化合物或其药学上可接受的盐，是免疫蛋白酶体（如 LMP2 和 LMP7）抑制剂。本文所述化合物可用于治疗可通过抑制免疫蛋白酶体治疗的疾病。本文还提供了含有此类化合物的药物组合物和制备此类化合物的工艺。
• Compositions and methods for the treatment of fungal infections
  申请人：Cellix Bio Private Limited

  公开号：US11220493B2

  公开（公告）日：2022-01-11

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶剂、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII、式 VIII、式 IX 或式 X 化合物的药物组合物以及治疗真菌感染的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。此类组合物可用于治疗真菌感染。